Overview

A Study to Assess the Safety and Efficacy of ADVAGRAF (Tacrolimus Modified Release Formulation) in Kidney Transplant Patients Who Were Treated With PROGRAF

Status:
Completed

Trial end date:
2013-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of tacrolimus modified release formulation Advagraf® after conversion from Prograf® in stable kidney transplant patients.

Phase:

Phase 4

Details

Lead Sponsor:

Astellas Pharma Korea, Inc.

Treatments:

Tacrolimus